Valuation: MediciNova, Inc.

Market Cap 99.43M 86.12M 81.44M 73.73M 138M 9.54B 139M 972M 374M 4.84B 373M 365M 15.42B P/E 2026 *
-7.67x
P/E 2027 * -5.32x
Enterprise Value 99.43M 86.12M 81.44M 73.73M 138M 9.54B 139M 972M 374M 4.84B 373M 365M 15.42B EV / Sales 2026 *
129x
EV / Sales 2027 * 199x
Free-Float
97.14%
Yield 2026 *
-
Yield 2027 * -
08-13 MediciNova, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-15 Medicinova Achieves Target Enrollment in Seanobi-Als Study Evaluating Mn-166 in Als Patients CI
06-08 MediciNova Receives Notice Of Allowance For New Patent Covering Use Of MN-166 In Combination With Anti-PD-1 Immune Checkpoint Inhibitor For Glioblastoma Treatment CI
06-08 MediciNova Granted US Patent Notice of Allowance for Ibudilast Combination to Treat Brain Cancer MT
05-26 MediciNova Announces Completion Of Last Patient Last Visit In The MN-001-NATG-202 Clinical Trial Of MN-001 CI
05-14 MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-16 HC Wainwright Initiates MediciNova at Buy With $10 Price Target MT
02-20 MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-30 MediciNova, Inc. Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access- Program Evaluating MN-166 in ALS Patients CI
12-30 MediciNova Inc enters $50 million equity distribution agreement with Lucid Capital Markets RE
12-18 MediciNova, Inc. Announces Completion of Patient Enrollment Evaluating MN-166 in the Prevention of Chemotherapy-Induced Peripheral Neuropathy CI
12-18 MediciNova Completes Enrollment in a Phase 2 Study of Colorectal Cancer Drug MT
12-08 MediciNova, Inc. Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 in ALS (COMBAT-ALS) in ALS Presented at the 36th International Symposium on ALS/MND CI
1 day+8.02%
1 week+15.43%
Current month+40.77%
1 month+54.20%
3 months+61.60%
6 months+49.63%
Current year+54.20%
1 week 1.72
Extreme 1.72
2.07
1 month 1.3
Extreme 1.3011
2.07
Current year 1.22
Extreme 1.22
2.07
1 year 1.17
Extreme 1.168
2.07
3 years 1.12
Extreme 1.12
2.55
5 years 1.12
Extreme 1.12
4.65
10 years 1.12
Extreme 1.12
14.5
Manager TitleAgeSince
Chief Executive Officer 76 2005-07-31
Director of Finance/CFO 49 2022-06-15
Chief Tech/Sci/R&D Officer 60 2011-08-31
Director TitleAgeSince
Chairman 76 2000-09-25
Director/Board Member 60 2019-07-23
Director/Board Member 69 2004-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
1/16/26 Free

Chief Technology Officer

350,000 0.7122%
1/16/26 Free

Chief Executive Officer

450,000 0.9156%
6/17/25 Free

Director

20,000 0.0408%
Change 5-day change 1-year change 3-year change Capi.($)
+8.02%+15.43%+62.90%-0.98% 99.43M
-1.38%+0.20%+46.42%+96.33% 69.18B
-0.56%-1.27%+35.46%+74.97% 62B
-4.29%-3.98%-16.22%+350.66% 26.19B
+1.46%+2.25%+28.84%+14.54% 25.75B
-2.20%-2.00%-1.22%-14.48% 24.29B
+3.63%+4.22%+25.33%-14.56% 19.84B
+1.26%-14.23%+170.04%+298.75% 15.65B
-5.54%+0.69%-8.13%+830.48% 13.88B
-0.39%-4.24%-9.86%+454.94% 14.09B
Average +0.00%-0.43%+33.36%+209.06% 27.1B
Weighted average by Cap. -0.91%-1.31%+31.80%+158.11%

Financials

2026 *2027 *
Net sales 772K 669K 633K 573K 1.08M 74.1M 1.08M 7.55M 2.9M 37.57M 2.9M 2.84M 120M 500K 433K 410K 371K 696K 47.96M 701K 4.89M 1.88M 24.32M 1.88M 1.84M 77.56M
Net income -13.39M -11.6M -10.97M -9.93M -18.64M -1.28B -18.78M -131M -50.35M -651M -50.3M -49.18M -2.08B -22.3M -19.32M -18.27M -16.54M -31.04M -2.14B -31.28M -218M -83.88M -1.08B -83.78M -81.92M -3.46B
Net Debt - -
Logo MediciNova, Inc.
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
Employees
6
Date Price Change Volume
26-09-15 US$2.020 +8.02% 207,205
26-09-14 US$1.870 +3.31% 68,480
26-09-11 US$1.810 +4.02% 45,965
26-09-10 US$1.740 -2.79% 70,051
26-09-09 US$1.790 +2.29% 106,276
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.020USD
Average target price
9.000USD
Spread / Average Target
+345.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNOV Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!